Results 281 to 290 of about 168,682 (384)

Lichen Planus Follicularis Tumidus

Australasian Journal of Dermatology, EarlyView.
A. I. Oloruntoba, Saurabh Prakash, Ryan Toholka   +2 more
wiley   +1 more source

CD123‐targeting immunotherapeutic approaches in acute myeloid leukaemia

British Journal of Haematology, EarlyView.
Summary Treatment of relapsed or refractory acute myeloid leukaemia (AML) has remained a significant challenge, with limited available targeted immunotherapies. CD123, or the interleukin‐3 (IL‐3) receptor, has long been known as a potential target expressed on AML blasts, and a range of different approaches to targeting CD123 have been trialled with ...
Alexandra Dreyzin, Noa G. Holtzman, Challice L. Bonifant   +2 more
wiley   +1 more source

Targeting CD20 [PDF]

, 2003
Jane N. Winter
openalex   +1 more source

Efficacy and safety of CD19 combined with CD22 or CD20 chimeric antigen receptor T-cell therapy for hematological malignancies. [PDF]

Front Immunol
Yuan X, Wang F, Zhao P, Yang B, Yang X, Tian T, Li B, Liu G, Wang S, Tang D, He Z, Li Y, Liu Y.   +12 more
europepmc   +1 more source

Anti-CD20 monoclonal antibody (rituximab) therapy for acute cardiac humoral rejection: a case report

, 2002
Juan M. Aranda, Juan C. Scornik, Sigurd J. Normann, Richard Lottenberg, Richard S. Schofield, Daniel Pauly, Maureen Miles, James A. Hill, John W. Sleasman, Suzanne Skoda‐Smith   +9 more
openalex   +1 more source

The efficacy and safety of B‐cell depletion with anti‐CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura [PDF]

, 2004
Nichola Cooper, Roberto Stasi, Susanna Cunningham–Rundles, Michael Feuerstein, John P. Leonard, Sergio Amadori, James B. Bussel   +6 more
openalex   +1 more source

Rituximab in Pemphigus - Exploring the Less Frequently Travelled Terrains. [PDF]

Indian Dermatol Online J
Rao R.
europepmc   +1 more source

Serum soluble interleukin‐2 receptor levels in hairy cell leukaemia as a marker of tumour burden with prognostic value and as a tool for disease monitoring

British Journal of Haematology, EarlyView.
Soluble interleukin‐2 receptor (sIL‐2R) is readily measurable in the serum of individuals affected by hairy cell leukaemia (HCL) and has the potential to become a marker of clinical utility. sIL‐2R levels reflect total HCL disease burden as demonstrated by their correlation with other indicators of tumour load.
Francesco Angotzi, Alessandro Cellini, Nicolò Danesin, Simone Zoletto, Andrea Serafin, Chiara Adele Cavarretta, Arianna Bevilacqua, Laura Forlani, Alessia Tonini, Federica Frezzato, Laura Bonaldi, Marco Pizzi, Diego Faggian, Livio Trentin, Andrea Visentin   +14 more
wiley   +1 more source

Anti-CD20 Monoclonal Antibody as a New Treatment Modality for B-Cell Lymphoma.

, 2002
Tomomitsu Hotta
openalex   +2 more sources

Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma [PDF]

, 2004
Andres Forero, Paul L. Weiden, Julie M. Vose, Susan J. Knox, Albert F. LoBuglio, Jordan Hankins, Michael L. Goris, Vincent J. Picozzi, Don B. Axworthy, Hazel B. Breitz, Robert B. Sims, Richard Ghalie, Sui Shen, Ruby F. Meredith   +13 more
openalex   +1 more source